Revision as of 13:33, 25 February 2023

Back to Top

Section editor
	Sanjay R. Mohan, MD, MSCI Vanderbilt University Nashville, TN

Are you looking for a regimen but can't find it here? For placebo or observational studies in this condition, please visit this page. If you still can't find it, please let us know so we can add it!

9 regimens on this page 11 variants on this page

This page covers the treatment of both primary and secondary myelofibrosis.

Guidelines

ESMO

2015: Vannucchi et al. Philadelphia chromosome-negative chronic myeloproliferative neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

NCCN

NCCN Guidelines - Myeloproliferative Neoplasms

All lines of therapy

Danazol monotherapy

Regimen

Study	Years of enrollment	Evidence	Comparator	Comparative Efficacy
Cervantes et al. 2005	NR in abstract	Non-randomized
Verstovsek et al. 2023 (MOMENTUM)	2020-2021	Phase 3 (C)	Momelotinib	Inferior TSS response rate at 24 weeks

Endocrine therapy

Danazol (Danocrine) 300 mg PO twice per day

Continued indefinitely

References

Cervantes F, Alvarez-Larrán A, Domingo A, Arellano-Rodrigo E, Montserrat E. Efficacy and tolerability of danazol as a treatment for the anaemia of myelofibrosis with myeloid metaplasia: long-term results in 30 patients. Br J Haematol. 2005 Jun;129(6):771-5. link to original article contains dosing details in abstract PubMed
MOMENTUM: Verstovsek S, Gerds AT, Vannucchi AM, Al-Ali HK, Lavie D, Kuykendall AT, Grosicki S, Iurlo A, Goh YT, Lazaroiu MC, Egyed M, Fox ML, McLornan D, Perkins A, Yoon SS, Gupta V, Kiladjian JJ, Granacher N, Lee SE, Ocroteala L, Passamonti F, Harrison CN, Klencke BJ, Ro S, Donahue R, Kawashima J, Mesa R; MOMENTUM Study Investigators. Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study. Lancet. 2023 Jan 28;401(10373):269-280. link to original article contains dosing details in abstract PubMed NCT04173494
PACIFICA: NCT03165734

Fedratinib monotherapy

Regimen

FDA-recommended dose

Study	Years of enrollment	Evidence	Comparator	Comparative Efficacy
Pardanani et al. 2015 (JAKARTA)	2011-2012	Phase 3 (E-RT-esc)	Fedratinib; 500 mg/d	Not reported
Pardanani et al. 2015 (JAKARTA)	2011-2012	Phase 3 (E-RT-esc)	Placebo	Superior RR

Targeted therapy

Fedratinib (Inrebic) 400 mg PO once per day

28-day cycles

References

JAKARTA: Pardanani A, Harrison C, Cortes JE, Cervantes F, Mesa RA, Milligan D, Masszi T, Mishchenko E, Jourdan E, Vannucchi AM, Drummond MW, Jurgutis M, Kuliczkowski K, Gheorghita E, Passamonti F, Neumann F, Patki A, Gao G, Tefferi A. Safety and efficacy of fedratinib in patients with primary or secondary myelofibrosis: A randomized clinical trial. JAMA Oncol. 2015 Aug 1;1(5):643-51. link to original article contains dosing details in manuscript PubMed NCT01437787

Hydroxyurea monotherapy

Regimen

Study	Years of enrollment	Evidence	Comparator	Comparative Efficacy
Mesa et al. 2017 (PERSIST-1)	2013-2014	Phase 3 (C)	Pacritinib	Inferior spleen volume reduction

Note: this was the most commonly used "best available therapy" (BAT) in PERSIST-1.

Chemotherapy

Hydroxyurea (Hydrea)

References

PERSIST-1: Mesa RA, Vannucchi AM, Mead A, Egyed M, Szoke A, Suvorov A, Jakucs J, Perkins A, Prasad R, Mayer J, Demeter J, Ganly P, Singer JW, Zhou H, Dean JP, Te Boekhorst PA, Nangalia J, Kiladjian JJ, Harrison CN. Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial. Lancet Haematol. 2017 May;4(5):e225-e236. Epub 2017 Mar 20. link to original article link to PMC article PubMed NCT01773187
PACIFICA: NCT03165734

Lenalidomide monotherapy

Regimen

Study	Evidence
Tefferi et al. 2006	Phase 2

Targeted therapy

Lenalidomide (Revlimid) 10 mg PO once per day

References

Tefferi A, Cortes J, Verstovsek S, Mesa RA, Thomas D, Lasho TL, Hogan WJ, Litzow MR, Allred JB, Jones D, Byrne C, Zeldis JB, Ketterling RP, McClure RF, Giles F, Kantarjian HM. Lenalidomide therapy in myelofibrosis with myeloid metaplasia. Blood. 2006 Aug 15;108(4):1158-64. Epub 2006 Apr 11. link to original article contains dosing details in abstract PubMed

Pacritinib monotherapy

Regimen

Study	Years of enrollment	Evidence	Comparator	Comparative Efficacy
Komrokji et al. 2015 (SB1518-2008-003)	2010	Phase 2
Mesa et al. 2017 (PERSIST-1)	2013-2014	Phase 3 (E-switch-ic)	"Best available therapy"	Superior spleen volume reduction
Mascarenhas et al. 2018 (PERSIST-2)	2014-2016	Phase 3 (E-RT-switch-ic)	"Best available therapy"	Superior spleen volume reduction

Targeted therapy

Pacritinib (Vonjo) 200 mg PO twice per day

Continued indefinitely

References

SB1518-2008-003: Komrokji RS, Seymour JF, Roberts AW, Wadleigh M, To LB, Scherber R, Turba E, Dorr A, Zhu J, Wang L, Granston T, Campbell MS, Mesa RA. Results of a phase 2 study of pacritinib (SB1518), a JAK2/JAK2(V617F) inhibitor, in patients with myelofibrosis. Blood. 2015 Apr 23;125(17):2649-55. Epub 2015 Mar 11. link to original article link to PMC article PubMed NCT00745550
PERSIST-1: Mesa RA, Vannucchi AM, Mead A, Egyed M, Szoke A, Suvorov A, Jakucs J, Perkins A, Prasad R, Mayer J, Demeter J, Ganly P, Singer JW, Zhou H, Dean JP, Te Boekhorst PA, Nangalia J, Kiladjian JJ, Harrison CN. Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial. Lancet Haematol. 2017 May;4(5):e225-e236. Epub 2017 Mar 20. link to original article link to PMC article PubMed NCT01773187
PERSIST-2: Mascarenhas J, Hoffman R, Talpaz M, Gerds AT, Stein B, Gupta V, Szoke A, Drummond M, Pristupa A, Granston T, Daly R, Al-Fayoumi S, Callahan JA, Singer JW, Gotlib J, Jamieson C, Harrison C, Mesa R, Verstovsek S. Pacritinib vs best available therapy, including ruxolitinib, in patients with myelofibrosis: a randomized clinical trial. JAMA Oncol. 2018 May 1;4(5):652-659. Epub 2018 Mar 8. link to original article link to PMC article contains dosing details in abstract PubMed NCT02055781

Pomalidomide monotherapy

Regimen variant #1

Study	Years of enrollment	Evidence	Comparator	Comparative Efficacy
Begna et al. 2010 (PO-MMM-PI-0007)	NR	Phase 2
Tefferi et al. 2016 (RESUME)	2010-2012	Phase 3 (E-esc)	Placebo	Did not meet primary endpoint of RBC-transfusion independence within 6 mo

Targeted therapy

Pomalidomide (Pomalyst) 0.5 mg PO once per day
- In PO-MMM-PI-0007, escalation up to 2 mg PO once per day allowed after first six cycles

28-day cycles

Regimen variant #2

Study	Years of enrollment	Evidence	Comparator	Comparative Efficacy
Tefferi et al. 2009 (CC-4047-MMM-001)	2007-NR	Randomized Phase 2 (E-esc)	1. Pomalidomide (2 mg/d) & Prednisone 2. Pomalidomide (0.5 mg/d) & Prednisone 3. Prednisone	Not reported

Targeted therapy

Pomalidomide (Pomalyst) 2 mg PO once per day

28-day cycles

References

CC-4047-MMM-001: Tefferi A, Verstovsek S, Barosi G, Passamonti F, Roboz GJ, Gisslinger H, Paquette RL, Cervantes F, Rivera CE, Deeg HJ, Thiele J, Kvasnicka HM, Vardiman JW, Zhang Y, Bekele BN, Mesa RA, Gale RP, Kantarjian HM. Pomalidomide is active in the treatment of anemia associated with myelofibrosis. J Clin Oncol. 2009 Sep 20;27(27):4563-9. Epub 2009 Aug 3. link to original article link to PMC article PubMed NCT00463385
PO-MMM-PI-0007: Begna KH, Mesa RA, Pardanani A, Hogan WJ, Litzow MR, McClure RF, Tefferi A. A phase-2 trial of low-dose pomalidomide in myelofibrosis. Leukemia. 2011 Feb;25(2):301-4. Epub 2010 Nov 5. trial protocol contains dosing details in manuscript PubMed
RESUME: Tefferi A, Al-Ali HK, Barosi G, Devos T, Gisslinger H, Jiang Q, Kiladjian JJ, Mesa R, Passamonti F, McMullin MF, Ribrag V, Schiller G, Vannucchi AM, Zhou D, Reiser D, Zhong J, Gale RP. A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependence. Leukemia. 2017 Apr;31(4):896-902. Epub 2016 Oct 24. link to original article contains dosing details in manuscript link to PMC article PubMed NCT01178281

Pomalidomide & Prednisone

Regimen variant #1

Study	Years of enrollment	Evidence	Comparator	Comparative Efficacy
Tefferi et al. 2009 (CC-4047-MMM-001)	2007-NR	Randomized Phase 2, <20 in this arm (E-esc)	1. Pomalidomide 2. Pomalidomide (0.5 mg/d) & Prednisone 3. Prednisone	Not reported

Targeted therapy

Pomalidomide (Pomalyst) 2 mg PO once per day

Glucocorticoid therapy

Prednisone (Sterapred) as follows:
- Cycle 1: 30 mg PO once per day
- Cycle 2: 15 mg PO once per day
- Cycle 3: 15 mg PO every other day

28-day cycles

Regimen variant #2

Study	Years of enrollment	Evidence	Comparator	Comparative Efficacy
Tefferi et al. 2009 (CC-4047-MMM-001)	2007-NR	Randomized Phase 2 (E-esc)	1. Pomalidomide 2. Pomalidomide (2 mg/d) & Prednisone 3. Prednisone	Not reported

Targeted therapy

Pomalidomide (Pomalyst) 0.5 mg PO once per day

Glucocorticoid therapy

Prednisone (Sterapred) as follows:
- Cycle 1: 30 mg PO once per day
- Cycle 2: 15 mg PO once per day
- Cycle 3: 15 mg PO every other day

28-day cycles

References

CC-4047-MMM-001: Tefferi A, Verstovsek S, Barosi G, Passamonti F, Roboz GJ, Gisslinger H, Paquette RL, Cervantes F, Rivera CE, Deeg HJ, Thiele J, Kvasnicka HM, Vardiman JW, Zhang Y, Bekele BN, Mesa RA, Gale RP, Kantarjian HM. Pomalidomide is active in the treatment of anemia associated with myelofibrosis. J Clin Oncol. 2009 Sep 20;27(27):4563-9. Epub 2009 Aug 3. link to original article link to PMC article PubMed NCT00463385

Prednisone monotherapy

Regimen

Study	Years of enrollment	Evidence	Comparator	Comparative Efficacy
Tefferi et al. 2009 (CC-4047-MMM-001)	2007-NR	Randomized Phase 2 (C)	1. Pomalidomide 2. Pomalidomide (2 mg/d) & Prednisone 3. Pomalidomide (0.5 mg/d) & Prednisone	Not reported

Glucocorticoid therapy

Prednisone (Sterapred) as follows:
- Cycle 1: 30 mg PO once per day
- Cycle 2: 15 mg PO once per day
- Cycle 3: 15 mg PO every other day

28-day cycle for 3 cycles

References

CC-4047-MMM-001: Tefferi A, Verstovsek S, Barosi G, Passamonti F, Roboz GJ, Gisslinger H, Paquette RL, Cervantes F, Rivera CE, Deeg HJ, Thiele J, Kvasnicka HM, Vardiman JW, Zhang Y, Bekele BN, Mesa RA, Gale RP, Kantarjian HM. Pomalidomide is active in the treatment of anemia associated with myelofibrosis. J Clin Oncol. 2009 Sep 20;27(27):4563-9. Epub 2009 Aug 3. link to original article link to PMC article PubMed NCT00463385
PACIFICA: NCT03165734

Ruxolitinib monotherapy

Regimen

COMFORT: COntrolled MyeloFibrosis Study with ORal JAK Inhibitor Treatment

Study	Years of enrollment	Evidence	Comparator	Comparative Efficacy
Verstovsek et al. 2010 (INCB 18424-251)	2007-NR	Phase 2
Verstovsek et al. 2012 (COMFORT-I)	2009-2010	Phase 3 (E-RT-esc)	Placebo	Seems to have superior OS¹ Median OS: NYR vs 200 weeks (HR 0.69, 95% CI 0.50-0.96)
Harrison et al. 2012 (COMFORT-II)	2009-2010	Phase 3 (E-RT-switch-ooc)	"Best available therapy"	Might have superior OS² Median OS: NYR vs 4.1 y (HR 0.67, 95% CI 0.44-1.02)
Al-Ali et al. 2016 (JUMP)	2011-2014	Phase 3b
Mead et al. 2015 (UK ROBUST)	2012-NR	Phase 2
Mesa et al. 2017 (SIMPLIFY-1)	2013-2016	Phase 3 (C)	Momelotinib	Non-inferior spleen response
Harrison et al. 2017 (SIMPLIFY-2)	2014-2016	Phase 3 (C)	Momelotinib	Did not meet primary endpoint of spleen volume reduction
Mascarenhas et al. 2018 (PERSIST-2)	2014-2016	Phase 3 (C)	Pacritinib	Inferior spleen volume reduction

¹Reported efficacy for COMFORT-I is based on the 2017 update.
²Reported efficacy for COMFORT-II is based on the 2016 update.
Note: Patients in COMFORT-II who received "best available therapy" (BAT) generally received no active treatment, Hydroxyurea (Hydrea), or glucocorticoids. Patients in SIMPLIFY-2 had been previously treated with ruxolitinib but were allowed to receive ruxolitinib as BAT. This was the most commonly used BAT in PERSIST-2.

Targeted therapy

Ruxolitinib (Jakafi) 10 to 25 mg PO twice per day

Continued indefinitely

References

INCB 18424-251: Verstovsek S, Kantarjian H, Mesa RA, Pardanani AD, Cortes-Franco J, Thomas DA, Estrov Z, Fridman JS, Bradley EC, Erickson-Viitanen S, Vaddi K, Levy R, Tefferi A. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med. 2010 Sep 16;363(12):1117-27. link to original article supplementary appendix contains dosing details in manuscript link to PMC article PubMed NCT00509899
COMFORT-I: Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger M, Miller C, Silver RT, Talpaz M, Winton EF, Harvey JH Jr, Arcasoy MO, Hexner E, Lyons RM, Paquette R, Raza A, Vaddi K, Erickson-Viitanen S, Koumenis IL, Sun W, Sandor V, Kantarjian HM. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012 Mar 1;366(9):799-807. link to original article supplementary appendix trial protocol contains dosing details in manuscript link to PMC article PubMed NCT00952289
1. Update: Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger MW, Miller CB, Silver RT, Talpaz M, Winton EF, Harvey JH, Arcasoy MO, Hexner EO, Lyons RM, Paquette R, Raza A, Vaddi K, Erickson-Viitanen S, Sun W, Sandor V, Kantarjian HM. Efficacy, safety and survival with ruxolitinib treatment in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I. Haematologica. 2013 Dec;98(12):1865-71. Epub 2013 Sep 13. link to original article link to PMC article PubMed
2. Update: Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger MW, Miller CB, Silver RT, Talpaz M, Winton EF, Harvey JH, Arcasoy MO, Hexner EO, Lyons RM, Raza A, Vaddi K, Sun W, Peng W, Sandor V, Kantarjian H. Three-year efficacy, overall survival, and safety of ruxolitinib therapy in patients with myelofibrosis from the COMFORT-I study. Haematologica. 2015 Apr;100(4):479-88. Epub 2015 Jan 23. link to original article link to PMC article PubMed
3. Pooled update: Vannucchi AM, Kantarjian HM, Kiladjian JJ, Gotlib J, Cervantes F, Mesa RA, Sarlis NJ, Peng W, Sandor V, Gopalakrishna P, Hmissi A, Stalbovskaya V, Gupta V, Harrison C, Verstovsek S; COMFORT Investigators. A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis. Haematologica. 2015 Sep;100(9):1139-45. Epub 2015 Jun 11. link to original article link to PMC article PubMed
4. Update: Verstovsek S, Mesa RA, Gotlib J, Gupta V, DiPersio JF, Catalano JV, Deininger MW, Miller CB, Silver RT, Talpaz M, Winton EF, Harvey JH Jr, Arcasoy MO, Hexner EO, Lyons RM, Paquette R, Raza A, Jones M, Kornacki D, Sun K, Kantarjian H; COMFORT-I investigators. Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial. J Hematol Oncol. 2017 Feb 22;10(1):55. link to original article link to PMC article PubMed
COMFORT-II: Harrison C, Kiladjian JJ, Al-Ali HK, Gisslinger H, Waltzman R, Stalbovskaya V, McQuitty M, Hunter DS, Levy R, Knoops L, Cervantes F, Vannucchi AM, Barbui T, Barosi G. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012 Mar 1;366(9):787-98. link to original article contains dosing details in manuscript PubMed content property of HemOnc.org NCT00934544
1. Update: Cervantes F, Vannucchi AM, Kiladjian JJ, Al-Ali HK, Sirulnik A, Stalbovskaya V, McQuitty M, Hunter DS, Levy RS, Passamonti F, Barbui T, Barosi G, Harrison CN, Knoops L, Gisslinger H. Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood. 2013 Dec 12;122(25):4047-53. Epub 2013 Oct 30. Erratum in: Blood. 2016 Dec 22;128(25):3013. link to original article PubMed
2. Pooled update: Vannucchi AM, Kantarjian HM, Kiladjian JJ, Gotlib J, Cervantes F, Mesa RA, Sarlis NJ, Peng W, Sandor V, Gopalakrishna P, Hmissi A, Stalbovskaya V, Gupta V, Harrison C, Verstovsek S; COMFORT Investigators. A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis. Haematologica. 2015 Sep;100(9):1139-45. Epub 2015 Jun 11. link to original article link to PMC article PubMed
3. Update: Harrison CN, Vannucchi AM, Kiladjian JJ, Al-Ali HK, Gisslinger H, Knoops L, Cervantes F, Jones MM, Sun K, McQuitty M, Stalbovskaya V, Gopalakrishna P, Barbui T. Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis. Leukemia. 2016 Aug;30(8):1701-7. Epub 2016 May 23. link to original article link to PMC article PubMed
UK ROBUST: Mead AJ, Milojkovic D, Knapper S, Garg M, Chacko J, Farquharson M, Yin J, Ali S, Clark RE, Andrews C, Ktiouet Dawson M, Harrison C. Response to ruxolitinib in patients with intermediate-1-, intermediate-2-, and high-risk myelofibrosis: results of the UK ROBUST Trial. Br J Haematol. 2015 Jul;170(1):29-39. Epub 2015 Mar 30. link to original article contains dosing details in abstract PubMed NCT01558739
JUMP: Al-Ali HK, Griesshammer M, le Coutre P, Waller CF, Liberati AM, Schafhausen P, Tavares R, Giraldo P, Foltz L, Raanani P, Gupta V, Tannir B, Ronco JP, Ghosh J, Martino B, Vannucchi AM. Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial. Haematologica. 2016 Sep;101(9):1065-73. Epub 2016 May 31. link to original article link to PMC article PubMed NCT01493414
SIMPLIFY-1: Mesa RA, Kiladjian JJ, Catalano JV, Devos T, Egyed M, Hellmann A, McLornan D, Shimoda K, Winton EF, Deng W, Dubowy RL, Maltzman JD, Cervantes F, Gotlib J. SIMPLIFY-1: a phase III randomized trial of momelotinib versus ruxolitinib in Janus kinase inhibitor-naïve patients with myelofibrosis. J Clin Oncol. 2017 Dec 1;35(34):3844-3850. Epub 2017 Sep 20. link to original article link to PMC article PubMed NCT01969838
SIMPLIFY-2: Harrison CN, Vannucchi AM, Platzbecker U, Cervantes F, Gupta V, Lavie D, Passamonti F, Winton EF, Dong H, Kawashima J, Maltzman JD, Kiladjian JJ, Verstovsek S. Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial. Lancet Haematol. 2018 Feb;5(2):e73-e81. Epub 2017 Dec 20. link to original article PubMed NCT02101268
PERSIST-2: Mascarenhas J, Hoffman R, Talpaz M, Gerds AT, Stein B, Gupta V, Szoke A, Drummond M, Pristupa A, Granston T, Daly R, Al-Fayoumi S, Callahan JA, Singer JW, Gotlib J, Jamieson C, Harrison C, Mesa R, Verstovsek S. Pacritinib vs best available therapy, including ruxolitinib, in patients with myelofibrosis: a randomized clinical trial. JAMA Oncol. 2018 May 1;4(5):652-659. Epub 2018 Mar 8. link to original article link to PMC article PubMed NCT02055781
PACIFICA: NCT03165734

Investigational agents

Momelotinib (CYT387)

@@ Line 18: / Line 18: @@
 <big>'''This page covers the treatment of both primary and secondary myelofibrosis.'''</big>
 {{TOC limit|limit=3}}
 =Guidelines=
 ==ESMO==
 *'''2015:''' Vannucchi et al. [https://www.esmo.org/Guidelines/Haematological-Malignancies/Philadelphia-Chromosome-Negative-Chronic-Myeloproliferative-Neoplasms Philadelphia chromosome-negative chronic myeloproliferative neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up]
 ==[https://www.nccn.org/ NCCN]==
 *[https://www.nccn.org/professionals/physician_gls/pdf/mpn.pdf NCCN Guidelines - Myeloproliferative Neoplasms]
 =All lines of therapy=
 ==Danazol monotherapy {{#subobject:962hgu|Regimen=1}}==
+<div class="toccolours" style="background-color:#eeeeee">
 ===Regimen {{#subobject:d8fbki|Variant=1}}===
 {| class="wikitable sortable" style="width: 100%; text-align:center;"
@@ Line 50: / Line 47: @@
 |-
 |}
+<div class="toccolours" style="background-color:#b3e2cd">
 ====Endocrine therapy====
 *[[Danazol (Danocrine)]] 300 mg PO twice per day
 '''Continued indefinitely'''
+</div></div>
 ===References===
 #Cervantes F, Alvarez-Larrán A, Domingo A, Arellano-Rodrigo E, Montserrat E. Efficacy and tolerability of danazol as a treatment for the anaemia of myelofibrosis with myeloid metaplasia: long-term results in 30 patients. Br J Haematol. 2005 Jun;129(6):771-5. [https://doi.org/10.1111/j.1365-2141.2005.05524.x link to original article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/15953003/ PubMed]
 #'''MOMENTUM:''' Verstovsek S, Gerds AT, Vannucchi AM, Al-Ali HK, Lavie D, Kuykendall AT, Grosicki S, Iurlo A, Goh YT, Lazaroiu MC, Egyed M, Fox ML, McLornan D, Perkins A, Yoon SS, Gupta V, Kiladjian JJ, Granacher N, Lee SE, Ocroteala L, Passamonti F, Harrison CN, Klencke BJ, Ro S, Donahue R, Kawashima J, Mesa R; MOMENTUM Study Investigators. Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study. Lancet. 2023 Jan 28;401(10373):269-280. [https://doi.org/10.1016/s0140-6736(22)02036-0 link to original article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/36709073/ PubMed] NCT04173494
 #'''PACIFICA:''' NCT03165734
 ==Fedratinib monotherapy {{#subobject:962af4|Regimen=1}}==
+<div class="toccolours" style="background-color:#eeeeee">
 ===Regimen {{#subobject:d87c8ki|Variant=1}}===
 {| class="wikitable" style="color:white; background-color:#404040"
@@ Line 84: / Line 80: @@
 |-
 |}
+<div class="toccolours" style="background-color:#b3e2cd">
 ====Targeted therapy====
 *[[Fedratinib (Inrebic)]] 400 mg PO once per day
 '''28-day cycles'''
+</div></div>
 ===References===
 # '''JAKARTA:''' Pardanani A, Harrison C, Cortes JE, Cervantes F, Mesa RA, Milligan D, Masszi T, Mishchenko E, Jourdan E, Vannucchi AM, Drummond MW, Jurgutis M, Kuliczkowski K, Gheorghita E, Passamonti F, Neumann F, Patki A, Gao G, Tefferi A. Safety and efficacy of fedratinib in patients with primary or secondary myelofibrosis: A randomized clinical trial. JAMA Oncol. 2015 Aug 1;1(5):643-51. [https://doi.org/10.1001/jamaoncol.2015.1590 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/26181658 PubMed] NCT01437787
 ==Hydroxyurea monotherapy {{#subobject:762af4|Regimen=1}}==
+<div class="toccolours" style="background-color:#eeeeee">
 ===Regimen {{#subobject:d87ecd|Variant=1}}===
 {| class="wikitable sortable" style="width: 100%; text-align:center;"
@@ Line 102: / Line 97: @@
 !style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 |-
-|[https://doi.org/10.1016/S2352-3026(17)30027-3 Mesa et al. 2017 (PERSIST-1)]
+|[https://www.ncbi.nlm.nih.gov/pmc/articles/pmc8209752/ Mesa et al. 2017 (PERSIST-1)]
 |2013-2014
 |style="background-color:#1a9851"|Phase 3 (C)
@@ Line 110: / Line 105: @@
 |}
 ''Note: this was the most commonly used "best available therapy" (BAT) in PERSIST-1.''
+<div class="toccolours" style="background-color:#b3e2cd">
 ====Chemotherapy====
 *[[Hydroxyurea (Hydrea)]]
+</div></div>
 ===References===
-# '''PERSIST-1:''' Mesa RA, Vannucchi AM, Mead A, Egyed M, Szoke A, Suvorov A, Jakucs J, Perkins A, Prasad R, Mayer J, Demeter J, Ganly P, Singer JW, Zhou H, Dean JP, Te Boekhorst PA, Nangalia J, Kiladjian JJ, Harrison CN. Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial. Lancet Haematol. 2017 May;4(5):e225-e236. Epub 2017 Mar 20. [https://doi.org/10.1016/S2352-3026(17)30027-3 link to original article] [https://pubmed.ncbi.nlm.nih.gov/28336242 PubMed] NCT01773187
+# '''PERSIST-1:''' Mesa RA, Vannucchi AM, Mead A, Egyed M, Szoke A, Suvorov A, Jakucs J, Perkins A, Prasad R, Mayer J, Demeter J, Ganly P, Singer JW, Zhou H, Dean JP, Te Boekhorst PA, Nangalia J, Kiladjian JJ, Harrison CN. Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial. Lancet Haematol. 2017 May;4(5):e225-e236. Epub 2017 Mar 20. [https://doi.org/10.1016/S2352-3026(17)30027-3 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc8209752/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/28336242 PubMed] NCT01773187
 #'''PACIFICA:''' NCT03165734
 ==Lenalidomide monotherapy {{#subobject:1 |Regimen=1}}==
+<div class="toccolours" style="background-color:#eeeeee">
 ===Regimen {{#subobject:1 |Variant=1}}===
 {| class="wikitable" style="width: 40%; text-align:center;"
@@ Line 129: / Line 123: @@
 |-
 |}
+<div class="toccolours" style="background-color:#b3e2cd">
 ====Targeted therapy====
 *[[Lenalidomide (Revlimid)]] 10 mg PO once per day
+</div></div>
 ===References===
 <!-- no pre-pub disclosed -->
 # Tefferi A, Cortes J, Verstovsek S, Mesa RA, Thomas D, Lasho TL, Hogan WJ, Litzow MR, Allred JB, Jones D, Byrne C, Zeldis JB, Ketterling RP, McClure RF, Giles F, Kantarjian HM. Lenalidomide therapy in myelofibrosis with myeloid metaplasia. Blood. 2006 Aug 15;108(4):1158-64. Epub 2006 Apr 11. [http://www.bloodjournal.org/content/108/4/1158.long link to original article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/16609064 PubMed]
 ==Pacritinib monotherapy {{#subobject:3ajbcx |Regimen=1}}==
+<div class="toccolours" style="background-color:#eeeeee">
 ===Regimen {{#subobject:4abjcc |Variant=1}}===
 {| class="wikitable sortable" style="width: 100%; text-align:center;"
@@ Line 152: / Line 146: @@
 | style="background-color:#d3d3d3" |
 |-
-|[https://doi.org/10.1016/S2352-3026(17)30027-3 Mesa et al. 2017 (PERSIST-1)]
+|[https://www.ncbi.nlm.nih.gov/pmc/articles/pmc8209752/ Mesa et al. 2017 (PERSIST-1)]
 |2013-2014
 |style="background-color:#1a9851"|Phase 3 (E-switch-ic)
@@ Line 165: / Line 159: @@
 |-
 |}
+<div class="toccolours" style="background-color:#b3e2cd">
 ====Targeted therapy====
 *[[Pacritinib (Vonjo)]] 200 mg PO twice per day
 '''Continued indefinitely'''
+</div></div>
 ===References===
 # '''SB1518-2008-003:''' Komrokji RS, Seymour JF, Roberts AW, Wadleigh M, To LB, Scherber R, Turba E, Dorr A, Zhu J, Wang L, Granston T, Campbell MS, Mesa RA. Results of a phase 2 study of pacritinib (SB1518), a JAK2/JAK2(V617F) inhibitor, in patients with myelofibrosis. Blood. 2015 Apr 23;125(17):2649-55. Epub 2015 Mar 11. [http://www.bloodjournal.org/content/125/17/2649.long link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc4490373/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/25762180 PubMed] NCT00745550
-# '''PERSIST-1:''' Mesa RA, Vannucchi AM, Mead A, Egyed M, Szoke A, Suvorov A, Jakucs J, Perkins A, Prasad R, Mayer J, Demeter J, Ganly P, Singer JW, Zhou H, Dean JP, Te Boekhorst PA, Nangalia J, Kiladjian JJ, Harrison CN. Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial. Lancet Haematol. 2017 May;4(5):e225-e236. Epub 2017 Mar 20. [https://doi.org/10.1016/S2352-3026(17)30027-3 link to original article] [https://pubmed.ncbi.nlm.nih.gov/28336242 PubMed] NCT01773187
+# '''PERSIST-1:''' Mesa RA, Vannucchi AM, Mead A, Egyed M, Szoke A, Suvorov A, Jakucs J, Perkins A, Prasad R, Mayer J, Demeter J, Ganly P, Singer JW, Zhou H, Dean JP, Te Boekhorst PA, Nangalia J, Kiladjian JJ, Harrison CN. Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial. Lancet Haematol. 2017 May;4(5):e225-e236. Epub 2017 Mar 20. [https://doi.org/10.1016/S2352-3026(17)30027-3 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc8209752/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/28336242 PubMed] NCT01773187
 # '''PERSIST-2:''' Mascarenhas J, Hoffman R, Talpaz M, Gerds AT, Stein B, Gupta V, Szoke A, Drummond M, Pristupa A, Granston T, Daly R, Al-Fayoumi S, Callahan JA, Singer JW, Gotlib J, Jamieson C, Harrison C, Mesa R, Verstovsek S. Pacritinib vs best available therapy, including ruxolitinib, in patients with myelofibrosis: a randomized clinical trial. JAMA Oncol. 2018 May 1;4(5):652-659. Epub 2018 Mar 8. [https://jamanetwork.com/journals/jamaoncology/fullarticle/2674384 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5885169/ link to PMC article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/29522138 PubMed] NCT02055781
 ==Pomalidomide monotherapy {{#subobject:3 |Regimen=1}}==
+<div class="toccolours" style="background-color:#eeeeee">
 ===Regimen variant #1 {{#subobject:4 |Variant=1}}===
 {| class="wikitable sortable" style="width: 100%; text-align:center;"
@@ Line 198: / Line 191: @@
 |-
 |}
+<div class="toccolours" style="background-color:#b3e2cd">
 ====Targeted therapy====
 *[[Pomalidomide (Pomalyst)]] 0.5 mg PO once per day
 **In PO-MMM-PI-0007, escalation up to 2 mg PO once per day allowed after first six cycles
 '''28-day cycles'''
+</div></div><br>
+<div class="toccolours" style="background-color:#eeeeee">
 ===Regimen variant #2 {{#subobject:3 |Variant=1}}===
 {| class="wikitable sortable" style="width: 100%; text-align:center;"
@@ Line 219: / Line 213: @@
 |-
 |}
+<div class="toccolours" style="background-color:#b3e2cd">
 ====Targeted therapy====
 *[[Pomalidomide (Pomalyst)]] 2 mg PO once per day
 '''28-day cycles'''
+</div></div>
 ===References===
 <!-- no pre-pub disclosed -->
@@ Line 229: / Line 223: @@
 # '''PO-MMM-PI-0007:''' Begna KH, Mesa RA, Pardanani A, Hogan WJ, Litzow MR, McClure RF, Tefferi A. A phase-2 trial of low-dose pomalidomide in myelofibrosis. Leukemia. 2011 Feb;25(2):301-4. Epub 2010 Nov 5. [https://doi.org/10.1038/leu.2010.254 trial protocol] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/21052089 PubMed]
 # '''RESUME:''' Tefferi A, Al-Ali HK, Barosi G, Devos T, Gisslinger H, Jiang Q, Kiladjian JJ, Mesa R, Passamonti F, McMullin MF, Ribrag V, Schiller G, Vannucchi AM, Zhou D, Reiser D, Zhong J, Gale RP. A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependence. Leukemia. 2017 Apr;31(4):896-902. Epub 2016 Oct 24. [https://doi.org/10.1038/leu.2016.300 link to original article] '''contains dosing details in manuscript''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5383927/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/27773929 PubMed] NCT01178281
 ==Pomalidomide & Prednisone {{#subobject:4 |Regimen=1}}==
+<div class="toccolours" style="background-color:#eeeeee">
 ===Regimen variant #1 {{#subobject:5 |Variant=1}}===
 {| class="wikitable sortable" style="width: 100%; text-align:center;"
@@ Line 248: / Line 240: @@
 |-
 |}
+<div class="toccolours" style="background-color:#b3e2cd">
 ====Targeted therapy====
 *[[Pomalidomide (Pomalyst)]] 2 mg PO once per day
@@ Line 255: / Line 248: @@
 **Cycle 2: 15 mg PO once per day
 **Cycle 3: 15 mg PO every other day
 '''28-day cycles'''
+</div></div><br>
+<div class="toccolours" style="background-color:#eeeeee">
 ===Regimen variant #2 {{#subobject:6 |Variant=1}}===
 {| class="wikitable sortable" style="width: 100%; text-align:center;"
@@ Line 273: / Line 266: @@
 |-
 |}
+<div class="toccolours" style="background-color:#b3e2cd">
 ====Targeted therapy====
 *[[Pomalidomide (Pomalyst)]] 0.5 mg PO once per day
@@ Line 280: / Line 274: @@
 **Cycle 2: 15 mg PO once per day
 **Cycle 3: 15 mg PO every other day
 '''28-day cycles'''
+</div></div>
 ===References===
 <!-- no pre-pub disclosed -->
 # '''CC-4047-MMM-001:''' Tefferi A, Verstovsek S, Barosi G, Passamonti F, Roboz GJ, Gisslinger H, Paquette RL, Cervantes F, Rivera CE, Deeg HJ, Thiele J, Kvasnicka HM, Vardiman JW, Zhang Y, Bekele BN, Mesa RA, Gale RP, Kantarjian HM. Pomalidomide is active in the treatment of anemia associated with myelofibrosis. J Clin Oncol. 2009 Sep 20;27(27):4563-9. Epub 2009 Aug 3. [https://doi.org/10.1200/jco.2008.21.7356 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4979191/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/19652059 PubMed] NCT00463385
 ==Prednisone monotherapy {{#subobject:5 |Regimen=1}}==
+<div class="toccolours" style="background-color:#eeeeee">
 ===Regimen {{#subobject:7 |Variant=1}}===
 {| class="wikitable sortable" style="width: 100%; text-align:center;"
@@ Line 305: / Line 296: @@
 |-
 |}
+<div class="toccolours" style="background-color:#b3e2cd">
 ====Glucocorticoid therapy====
 *[[Prednisone (Sterapred)]] as follows:
@@ Line 310: / Line 302: @@
 **Cycle 2: 15 mg PO once per day
 **Cycle 3: 15 mg PO every other day
 '''28-day cycle for 3 cycles'''
+</div></div>
 ===References===
 <!-- no pre-pub disclosed -->
 # '''CC-4047-MMM-001:''' Tefferi A, Verstovsek S, Barosi G, Passamonti F, Roboz GJ, Gisslinger H, Paquette RL, Cervantes F, Rivera CE, Deeg HJ, Thiele J, Kvasnicka HM, Vardiman JW, Zhang Y, Bekele BN, Mesa RA, Gale RP, Kantarjian HM. Pomalidomide is active in the treatment of anemia associated with myelofibrosis. J Clin Oncol. 2009 Sep 20;27(27):4563-9. Epub 2009 Aug 3. [https://doi.org/10.1200/jco.2008.21.7356 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4979191/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/19652059 PubMed] NCT00463385
 #'''PACIFICA:''' NCT03165734
 ==Ruxolitinib monotherapy {{#subobject:6 |Regimen=1}}==
+<div class="toccolours" style="background-color:#eeeeee">
 ===Regimen {{#subobject:8 |Variant=1}}===
 COMFORT: '''<u>CO</u>'''ntrolled '''<u>M</u>'''yelo'''<u>F</u>'''ibrosis Study with '''<u>OR</u>'''al JAK Inhibitor '''<u>T</u>'''reatment
 {| class="wikitable sortable" style="width: 100%; text-align:center;"
 !style="width: 20%"|Study
@@ Line 361: / Line 349: @@
 |style="background-color:#d3d3d3"|
 |-
-|[https://doi.org/10.1200/JCO.2017.73.4418 Mesa et al. 2017 (SIMPLIFY-1)]
+|[https://www.ncbi.nlm.nih.gov/pmc/articles/pmc6553796/ Mesa et al. 2017 (SIMPLIFY-1)]
 |2013-2016
 |style="background-color:#1a9851"|Phase 3 (C)
@@ Line 382: / Line 370: @@
 ''<sup>1</sup>Reported efficacy for COMFORT-I is based on the 2017 update.''<br>
 ''<sup>2</sup>Reported efficacy for COMFORT-II is based on the 2016 update.''<br>
-''Patients in COMFORT-II who received "best available therapy" (BAT) generally received no active treatment, [[Hydroxyurea (Hydrea)]], or [[:Category:Steroids|glucocorticoids]]. Patients in SIMPLIFY-2 had been previously treated with ruxolitinib but were allowed to receive ruxolitinib as BAT. This was the most commonly used BAT in PERSIST-2.''
+''Note: Patients in COMFORT-II who received "best available therapy" (BAT) generally received no active treatment, [[Hydroxyurea (Hydrea)]], or [[:Category:Steroids|glucocorticoids]]. Patients in SIMPLIFY-2 had been previously treated with ruxolitinib but were allowed to receive ruxolitinib as BAT. This was the most commonly used BAT in PERSIST-2.''
+<div class="toccolours" style="background-color:#b3e2cd">
 ====Targeted therapy====
 *[[Ruxolitinib (Jakafi)]] 10 to 25 mg PO twice per day
 '''Continued indefinitely'''
+</div></div>
 ===References===
 # '''INCB 18424-251:''' Verstovsek S, Kantarjian H, Mesa RA, Pardanani AD, Cortes-Franco J, Thomas DA, Estrov Z, Fridman JS, Bradley EC, Erickson-Viitanen S, Vaddi K, Levy R, Tefferi A. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med. 2010 Sep 16;363(12):1117-27. [https://doi.org/10.1056/NEJMoa1002028 link to original article] [https://www.nejm.org/doi/suppl/10.1056/NEJMoa1002028/suppl_file/nejmoa1002028_appendix.pdf supplementary appendix] '''contains dosing details in manuscript''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5187954/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/20843246 PubMed]  NCT00509899
@@ Line 401: / Line 389: @@
 # '''UK ROBUST:''' Mead AJ, Milojkovic D, Knapper S, Garg M, Chacko J, Farquharson M, Yin J, Ali S, Clark RE, Andrews C, Ktiouet Dawson M, Harrison C. Response to ruxolitinib in patients with intermediate-1-, intermediate-2-, and high-risk myelofibrosis: results of the UK ROBUST Trial. Br J Haematol. 2015 Jul;170(1):29-39. Epub 2015 Mar 30. [https://doi.org/10.1111/bjh.13379 link to original article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/25824940 PubMed] NCT01558739
 # '''JUMP:''' Al-Ali HK, Griesshammer M, le Coutre P, Waller CF, Liberati AM, Schafhausen P, Tavares R, Giraldo P, Foltz L, Raanani P, Gupta V, Tannir B, Ronco JP, Ghosh J, Martino B, Vannucchi AM. Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial. Haematologica. 2016 Sep;101(9):1065-73. Epub 2016 May 31. [http://www.haematologica.org/content/101/9/1065.abstract link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5060023/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/27247324 PubMed] NCT01493414
-# '''SIMPLIFY-1:''' Mesa RA, Kiladjian JJ, Catalano JV, Devos T, Egyed M, Hellmann A, McLornan D, Shimoda K, Winton EF, Deng W, Dubowy RL, Maltzman JD, Cervantes F, Gotlib J. SIMPLIFY-1: a phase III randomized trial of momelotinib versus ruxolitinib in Janus kinase inhibitor-naïve patients with myelofibrosis. J Clin Oncol. 2017 Dec 1;35(34):3844-3850. Epub 2017 Sep 20. [https://doi.org/10.1200/JCO.2017.73.4418 link to original article] [https://pubmed.ncbi.nlm.nih.gov/28930494 PubMed] NCT01969838
+# '''SIMPLIFY-1:''' Mesa RA, Kiladjian JJ, Catalano JV, Devos T, Egyed M, Hellmann A, McLornan D, Shimoda K, Winton EF, Deng W, Dubowy RL, Maltzman JD, Cervantes F, Gotlib J. SIMPLIFY-1: a phase III randomized trial of momelotinib versus ruxolitinib in Janus kinase inhibitor-naïve patients with myelofibrosis. J Clin Oncol. 2017 Dec 1;35(34):3844-3850. Epub 2017 Sep 20. [https://doi.org/10.1200/JCO.2017.73.4418 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc6553796/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/28930494 PubMed] NCT01969838
 # '''SIMPLIFY-2:''' Harrison CN, Vannucchi AM, Platzbecker U, Cervantes F, Gupta V, Lavie D, Passamonti F, Winton EF, Dong H, Kawashima J, Maltzman JD, Kiladjian JJ, Verstovsek S. Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial. Lancet Haematol. 2018 Feb;5(2):e73-e81. Epub 2017 Dec 20. [https://doi.org/10.1016/S2352-3026(17)30237-5 link to original article] [https://pubmed.ncbi.nlm.nih.gov/29275119 PubMed] NCT02101268
 # '''PERSIST-2:''' Mascarenhas J, Hoffman R, Talpaz M, Gerds AT, Stein B, Gupta V, Szoke A, Drummond M, Pristupa A, Granston T, Daly R, Al-Fayoumi S, Callahan JA, Singer JW, Gotlib J, Jamieson C, Harrison C, Mesa R, Verstovsek S. Pacritinib vs best available therapy, including ruxolitinib, in patients with myelofibrosis: a randomized clinical trial. JAMA Oncol. 2018 May 1;4(5):652-659. Epub 2018 Mar 8. [https://jamanetwork.com/journals/jamaoncology/fullarticle/2674384 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5885169/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/29522138 PubMed] NCT02055781
 #'''PACIFICA:''' NCT03165734
 =Investigational agents=
 *[[Momelotinib (CYT387)]]
 [[Category:Myelofibrosis regimens]]
 [[Category:Disease-specific pages]]
 [[Category:Myeloproliferative neoplasms]]

Difference between revisions of "Myelofibrosis"

Revision as of 13:33, 25 February 2023

Guidelines

ESMO

NCCN

All lines of therapy

Danazol monotherapy

Regimen

Endocrine therapy

References

Fedratinib monotherapy

Regimen

Targeted therapy

References

Hydroxyurea monotherapy

Regimen

Chemotherapy

References

Lenalidomide monotherapy

Regimen

Targeted therapy

References

Pacritinib monotherapy

Regimen

Targeted therapy

References

Pomalidomide monotherapy

Regimen variant #1

Targeted therapy

Regimen variant #2

Targeted therapy

References

Pomalidomide & Prednisone

Regimen variant #1

Targeted therapy

Glucocorticoid therapy

Regimen variant #2

Targeted therapy

Glucocorticoid therapy

References

Prednisone monotherapy

Regimen

Glucocorticoid therapy

References

Ruxolitinib monotherapy

Regimen

Targeted therapy

References

Investigational agents

Navigation menu

Search